EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte Studie

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

Marco Ruella, Luca Paruzzo, Emeline R Chong, Elise A Chong iD, Daniel J Landsburg, Sunita D Nasta, Pooja Devi, Peter Michener, Federico Stella iD, Alberto Carturan, Ellen B Napier, Vivianna M Van Deerlin und 8 weitere

New England Journal of Medicine · 25.06.2026 · 394 (24) · 2440-2448

DOI: 10.1056/nejmoa2518035 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 25.06.2026. Verfasst von Marco Ruella und 19 weiteren Autor:innen. Beteiligte Einrichtung: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Second Primary. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: NCI NIH HHS, NIH HHS, NCI NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveLymphoma, FollicularLymphoma, Large B-Cell, DiffuseNeoplasms, Second PrimaryReceptors, Antigen, T-CellAgedFemaleHumansMaleMiddle AgedAntigens, CD19Follow-Up StudiesReceptors, Chimeric AntigenRecurrenceT-LymphocytesDrug Resistance, NeoplasmDisease-Free SurvivalIncidenceNeutropenia

Substanzen

Antigens, CD19Receptors, Antigen, T-CellReceptors, Chimeric Antigentisagenlecleucel

Autor:innen und Institutionen

  • Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia.
  • Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia.
  • Department of Medicine, Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia.
  • Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia.
  • Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

ORCID-Profile: Elise A Chong, Federico Stella, Carl H June

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NCI NIH
  • Berman and Maguire Funds for Lymphoma Research at PennU
  • Laffey-McHugh Foundation

Zitieren

APA

Ruella, M., Paruzzo, L., Chong, E. R., Chong, E. A., Landsburg, D. J., Nasta, S. D., Devi, P., Michener, P., Stella, F., Carturan, A., Napier, E. B., Van Deerlin, V. M., Porazzi, P., Levine, B. L., Frey, N., Porter, D. L., Fraietta, J. A., Svoboda, J., June, C. H., & Schuster, S. J. (2026). Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. New England Journal of Medicine, 394(24), 2440-2448. https://doi.org/10.1056/nejmoa2518035

Vancouver

Ruella M, Paruzzo L, Chong ER, Chong EA, Landsburg DJ, Nasta SD, et al. Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. New England Journal of Medicine. 2026;394(24):2440-2448. doi:10.1056/nejmoa2518035

BibTeX
@article{Ruella2026,
  author = {Ruella, Marco and Paruzzo, Luca and Chong, Emeline R and Chong, Elise A and Landsburg, Daniel J and Nasta, Sunita D and Devi, Pooja and Michener, Peter and Stella, Federico and Carturan, Alberto and Napier, Ellen B and Van Deerlin, Vivianna M and Porazzi, Patrizia and Levine, Bruce L and Frey, Noelle and Porter, David L and Fraietta, Joseph A and Svoboda, Jakub and June, Carl H and Schuster, Stephen J},
  title = {Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {24},
  pages = {2440--2448},
  doi = {10.1056/nejmoa2518035}
}
Kostenlos starten →